Total Payments
$16,197
2024 Payments
$1,750
Companies
8
Transactions
64
Medicare Patients
387
Medicare Billing
$384,227
Payment Breakdown by Category
Travel$7,627 (47.1%)
Research$5,202 (32.1%)
Food & Beverage$2,209 (13.6%)
Consulting$1,160 (7.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Travel and Lodging | $7,627 | 21 | 47.1% |
| Unspecified | $5,202 | 16 | 32.1% |
| Food and Beverage | $2,209 | 26 | 13.6% |
| Consulting Fee | $1,160 | 1 | 7.2% |
Payments by Type
General
$10,995
48 transactions
Research
$5,202
16 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca UK Limited | $5,030 | 21 | $0 (2023) |
| Merck Sharp & Dohme LLC | $3,770 | 16 | $0 (2024) |
| Eli Lilly and Company | $3,633 | 3 | $0 (2023) |
| Gilead Sciences, Inc. | $1,569 | 13 | $0 (2019) |
| Celgene Corporation | $1,060 | 7 | $0 (2018) |
| ModernaTX, Inc. | $716.73 | 2 | $0 (2023) |
| Novo Nordisk AS | $400.00 | 1 | $0 (2019) |
| Cardiovascular Systems Inc. | $18.83 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,750 | 8 | Merck Sharp & Dohme LLC ($1,750) |
| 2023 | $2,008 | 10 | AstraZeneca UK Limited ($990.86) |
| 2022 | $5,996 | 7 | Eli Lilly and Company ($3,333) |
| 2020 | $860.17 | 7 | Merck Sharp & Dohme Corporation ($860.17) |
| 2019 | $4,523 | 25 | AstraZeneca UK Limited ($2,554) |
| 2018 | $1,060 | 7 | Celgene Corporation ($1,060) |
All Payment Transactions
64 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/18/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $959.51 | General |
| Category: ENDOCRINOLOGY | ||||||
| 06/18/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $202.50 | General |
| Category: ENDOCRINOLOGY | ||||||
| 06/18/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $118.00 | General |
| Category: ENDOCRINOLOGY | ||||||
| 06/18/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $48.03 | General |
| Category: ENDOCRINOLOGY | ||||||
| 06/18/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $34.99 | General |
| Category: ENDOCRINOLOGY | ||||||
| 06/18/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $29.99 | General |
| Category: ENDOCRINOLOGY | ||||||
| 06/17/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $235.55 | General |
| Category: ENDOCRINOLOGY | ||||||
| 06/17/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $121.01 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/04/2023 | AstraZeneca UK Limited | — | Travel and Lodging | In-kind items and services | $493.06 | General |
| 12/04/2023 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 12/04/2023 | AstraZeneca UK Limited | — | Travel and Lodging | In-kind items and services | $134.20 | General |
| 12/04/2023 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $96.42 | General |
| 12/04/2023 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $47.08 | General |
| 12/04/2023 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $46.00 | General |
| 12/04/2023 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $39.10 | General |
| 08/17/2023 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $541.80 | General |
| 08/17/2023 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $174.93 | General |
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $300.00 | Research |
| Study: A SINGLE-ASCENDING AND REPEATED SUBCUTANEOUS DOSE STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF LY3849891 IN PARTICIPANTS WITH NONALCOHOLIC FATTY LIVER DISEASE WHO HAVE THE PNPLA3 I148M GENOTYPE | ||||||
| 12/07/2022 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,160.00 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/01/2022 | AstraZeneca UK Limited | — | Travel and Lodging | In-kind items and services | $767.20 | General |
| 12/01/2022 | AstraZeneca UK Limited | — | Travel and Lodging | In-kind items and services | $462.16 | General |
| 12/01/2022 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $255.00 | General |
| 04/21/2022 | Eli Lilly and Company | — | — | In-kind items and services | $1,110.00 | Research |
| Study: A SINGLE-ASCENDING AND REPEATED SUBCUTANEOUS DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3849891 IN PARTICIPANTS WITH NONALCOHOLIC FATTY LIVER DISEASE WHO HAVE THE PNPLA3 I148M GENOTYPE | ||||||
| 03/25/2022 | Cardiovascular Systems Inc. | Diamondback Peripheral (Device) | Food and Beverage | Cash or cash equivalent | $18.83 | General |
| Category: Atherectomy Device | ||||||
| 01/26/2022 | Eli Lilly and Company | — | — | In-kind items and services | $2,223.00 | Research |
| Study: PRESCREENING STUDY FOR PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) WHO ARE CARRIERS OF THE PNPLA3 I148M ALLELE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PRESCREENING STUDY FOR PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) WHO ARE CARRIERS OF THE PNPLA3 I148M ALLELE | Eli Lilly and Company | $2,223 | 1 |
| A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | Gilead Sciences, Inc. | $1,466 | 10 |
| A SINGLE-ASCENDING AND REPEATED SUBCUTANEOUS DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3849891 IN PARTICIPANTS WITH NONALCOHOLIC FATTY LIVER DISEASE WHO HAVE THE PNPLA3 I148M GENOTYPE | Eli Lilly and Company | $1,110 | 1 |
| A SINGLE-ASCENDING AND REPEATED SUBCUTANEOUS DOSE STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF LY3849891 IN PARTICIPANTS WITH NONALCOHOLIC FATTY LIVER DISEASE WHO HAVE THE PNPLA3 I148M GENOTYPE | Eli Lilly and Company | $300.00 | 1 |
| A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with HIV-1 Infection with Multidrug Resistance | Gilead Sciences, Inc. | $102.42 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 46 | 854 | $140,100 | $52,789 |
| 2022 | 3 | 86 | 1,619 | $173,600 | $95,718 |
| 2021 | 4 | 102 | 1,942 | $208,500 | $117,201 |
| 2020 | 7 | 153 | 1,837 | $214,660 | $118,518 |
Total Patients
387
Total Services
6,252
Medicare Billing
$384,227
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Facility | 2023 | 27 | 829 | $134,740 | $50,076 | 37.2% |
| 99305 | Initial nursing facility care with moderate level of medical decision making, per day, if using time, at least 35 minutes | Facility | 2023 | 19 | 25 | $5,360 | $2,713 | 50.6% |
| 99308 | Follow-up nursing facility visit per day, typically 15 minutes | Facility | 2022 | 37 | 1,433 | $143,300 | $80,469 | 56.2% |
| 99309 | Follow-up nursing facility visit per day, typically 25 minutes | Facility | 2022 | 14 | 138 | $20,700 | $10,225 | 49.4% |
| 99305 | Initial nursing facility visit per day, typically 35 minutes | Facility | 2022 | 35 | 48 | $9,600 | $5,025 | 52.3% |
| 99308 | Subsequent nursing facility visit, typically 15 minutes per day | Facility | 2021 | 42 | 1,713 | $171,300 | $97,584 | 57.0% |
| 99309 | Subsequent nursing facility visit, typically 25 minutes per day | Facility | 2021 | 12 | 169 | $25,350 | $12,724 | 50.2% |
| 99305 | Initial nursing facility visit, typically 35 minutes per day | Facility | 2021 | 34 | 45 | $9,000 | $4,824 | 53.6% |
| 99306 | Initial nursing facility visit, typically 45 minutes per day | Facility | 2021 | 14 | 15 | $2,850 | $2,070 | 72.6% |
| 99308 | Subsequent nursing facility visit, typically 15 minutes per day | Facility | 2020 | 42 | 1,293 | $129,300 | $73,761 | 57.0% |
| 99309 | Subsequent nursing facility visit, typically 25 minutes per day | Facility | 2020 | 25 | 446 | $66,900 | $33,579 | 50.2% |
| 99305 | Initial nursing facility visit, typically 35 minutes per day | Facility | 2020 | 22 | 34 | $6,800 | $3,676 | 54.1% |
| 99306 | Initial nursing facility visit, typically 45 minutes per day | Facility | 2020 | 24 | 24 | $4,560 | $3,345 | 73.4% |
| 99220 | Hospital observation care, typically 70 minutes | Facility | 2020 | 15 | 15 | $3,750 | $2,320 | 61.9% |
| 99316 | Nursing facility discharge management, more than 30 minutes | Facility | 2020 | 12 | 12 | $1,920 | $1,052 | 54.8% |
| 99217 | Hospital observation care on day of discharge | Facility | 2020 | 13 | 13 | $1,430 | $785.45 | 54.9% |
About Dr. William Sanchez, M.D
Dr. William Sanchez, M.D is a Internal Medicine healthcare provider based in Hialeah, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1659321636.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William Sanchez, M.D has received a total of $16,197 in payments from pharmaceutical and medical device companies, with $1,750 received in 2024. These payments were reported across 64 transactions from 8 companies. The most common payment nature is "Travel and Lodging" ($7,627).
As a Medicare-enrolled provider, Sanchez has provided services to 387 Medicare beneficiaries, totaling 6,252 services with total Medicare billing of $384,227. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Hialeah, FL
- Active Since 05/11/2006
- Last Updated 07/10/2012
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1659321636
Products in Payments
- Ozanimod (Drug) $1,060
- MK-8591A (Drug) $860.17
- Diamondback Peripheral (Device) $18.83
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Hialeah
Miguel Diaz, Md, MD
Internal Medicine — Payments: $472,891
Internal Medicine $472,891
Karelia Ruiz
Internal Medicine — Payments: $114,006
Internal Medicine $114,006
Dr. Francisco Rosas, M.d, M.D
Internal Medicine — Payments: $105,387
Internal Medicine $105,387
Dr. Miguel Perez, M.d, M.D
Internal Medicine — Payments: $86,695
Internal Medicine $86,695
Dr. Jorge Diaz, D.o, D.O
Internal Medicine — Payments: $15,027
Internal Medicine $15,027
Dr. Scott Halperin, M.d, M.D
Internal Medicine — Payments: $14,253
Internal Medicine $14,253